82P A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX

M-H Su

doi:10.1016/j.annonc.2022.10.118

82P A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX

M-H Su

Open Access

https://doi.org/10.1016/j.annonc.2022.10.118

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
Citations: 2	License type: publisher-specific-oa

Affiliation: National Defense Medical Center

#Advanced Pancreatic Ductal Adenocarcinoma #Paclitaxel In Cationic Liposomes + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

FOLFIRINOX is a global standard first-line (1L) treatment for advanced pancreatic ductal adenocarcinoma (APDAC), but the second-line option after its failure remains yet defined. Current study evaluated the efficacy and safety of EndoTAG-1 (paclitaxel in cationic liposomes) plus gemcitabine as a second-line treatment in APDAC after FOLFIRINOX.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.